OxyContin

OxyContin is a brand name of oxycodone, approved by the FDA in the following formulation(s):

OXYCONTIN (oxycodone hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: PURDUE PHARMA LP
  
  Approval date: April 5, 2010
  
  Strength(s): 10MG, 15MG, 20MG, 30MG, 40MG ^[RLD], 60MG, 80MG
  

Has a generic version of OxyContin been approved?

No. There is currently no therapeutically equivalent version of OxyContin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of OxyContin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Controlled release oxycodone compositions
  Patent 5,508,042
  Issued: April 16, 1996
  Inventor(s): Oshlack; Benjamin & Chasin; Mark & Minogue; John J. & Kaiko; Robert F.
  Assignee(s): Euro-Celtigue, S.A.
  A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e. every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
  
  Patent expiration dates:
  
  
  • April 16, 2013
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
  
  



• 
  Hot-melt extrudable pharmaceutical formulation
  Patent 6,488,963
  Issued: December 3, 2002
  Inventor(s): James W.; McGinity & Feng; Zhang
  Assignee(s): The University of Texas System
  The present invention relates to pharmaceutical formulations comprising a hot-melt extrudable mixture of a therapeutic compound and a high molecular weight poly(ethylene oxide) in an essentially non-film like preparation. In some embodiments, the formulation further comprises poly(ethylene glycol). The present invention also includes efficient methods for hot-melt extruding pharmaceutical formulations in essentially non-film preparations.
  
  Patent expiration dates:
  
  
  • June 24, 2017
    
    ✓ 
    Drug product
  
  



• 
  Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
  Patent 7,674,799
  Issued: March 9, 2010
  Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
  Assignee(s): Purdue Pharma L.P.
  In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
  
  Patent expiration dates:
  
  
  • March 30, 2025
    
    ✓ 
    Drug product
  
  



• 
  Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
  Patent 7,674,800
  Issued: March 9, 2010
  Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
  Assignee(s): Purdue Pharma L.P.
  In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
  
  Patent expiration dates:
  
  
  • March 30, 2025
    
    ✓ 
    Drug substance
  
  



• 
  Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
  Patent 7,683,072
  Issued: March 23, 2010
  Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
  Assignee(s): Purdue Pharma L.P.
  In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
  
  Patent expiration dates:
  
  
  • March 30, 2025
    
    ✓ 
    Drug substance
  
  



• 
  Abuse-proofed dosage system
  Patent 7,776,314
  Issued: August 17, 2010
  Inventor(s): Bartholomäus; Johannes & Kugelmann; Heinrich
  Assignee(s): Grunenthal GmbH
  The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
  
  Patent expiration dates:
  
  
  • April 19, 2025
    
    ✓ 
    Drug product
  
  



• 
  Abuse-proofed dosage form
  Patent 8,114,383
  Issued: February 14, 2012
  Inventor(s): Bartholomäus; Johannes & Kugelmann; Heinrich & Arkenau-Marić; Elisabeth
  Assignee(s): Gruenenthal GmbH
  The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
  
  Patent expiration dates:
  
  
  • October 10, 2024
    
    ✓ 
    Drug product
  
  

See also...

• Oxycontin Consumer Information (Drugs.com)
• OxyContin Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• OxyContin Consumer Information (Cerner Multum)
• Oxycontin Advanced Consumer Information (Micromedex)
• Oxycodone Consumer Information (Drugs.com)
• Oxycodone Consumer Information (Wolters Kluwer)
• Oxycodone Concentrate Consumer Information (Wolters Kluwer)
• Oxycodone Solution Consumer Information (Wolters Kluwer)
• Oxycodone Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Oxycodone Consumer Information (Cerner Multum)
• Oxy IR Advanced Consumer Information (Micromedex)
• Oxycontin CR Advanced Consumer Information (Micromedex)
• Oxycodone Advanced Consumer Information (Micromedex)
• Oxycodone AHFS DI Monographs (ASHP)
• Oxycodone Hydrochloride AHFS DI Monographs (ASHP)